PT  - JOURNAL ARTICLE
AU  - Rossignol, Jean-François
AU  - Bardin, Matthew C.
AU  - Oaks, Joshua B.
AU  - Bostick, B. Gregory
AU  - Vora, Kishor N.
AU  - Fulgencio, Jessica
AU  - Mogelnicki, Dena
AU  - Bréchot, Christian
AU - for the Vanguard Study Group
TI  - Early treatment with nitazoxanide prevents worsening of mild and moderate COVID-19 and subsequent hospitalization
AID  - 10.1101/2021.04.19.21255441
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.04.19.21255441
4099  - http://medrxiv.org/content/early/2021/04/20/2021.04.19.21255441.short
4100  - http://medrxiv.org/content/early/2021/04/20/2021.04.19.21255441.full
AB  - Background There is an urgent need for treatments to prevent the progression to severe COVID-19 and hospitalization.Methods This is a double-blind randomized multicenter study in 36 centers in the U.S. and Puerto Rico investigating the potential of a five-day treatment with nitazoxanide 300 mg extended release tablets in 379 outpatients with mild or moderate laboratory-confirmed COVID-19 with an onset of symptoms no more than 72 hours before inclusion. Key objectives were reduction of duration of symptoms (primary), progression to severe illness (key secondary), hospitalization and viral load.Results Time to sustained response was not reduced by nitazoxanide (median: 13.28 and 12.35 days for nitazoxanide and placebo). Nitazoxanide treatment provided an 85% reduction in the progression to severe COVID-19 (1/184, [0.5%] nitazoxanide vs. 7/195, [3.6%] placebo). In subjects at high-risk according to CDC criteria, 1/112 (0.9%) of nitazoxanide-treated subjects and 7/126 (5.6%) of placebo-treated subjects experienced progression to severe COVID-19. Treatment led to a 79% reduction in the rate of hospitalization (1/184 [0.5%] nitazoxanide vs. 5/195 [2.6%] placebo). The proportions positive for SARS-CoV-2 RNA and viral load at days 4 and 10 were not reduced. Nitazoxanide was safe and well tolerated.Conclusions Treatment of mild or moderate COVID-19 with a five-day course of oral nitazoxanide was safe and well tolerated and was associated with an 85% reduction in the progression to severe illness.Competing Interest StatementJean-Francois Rossignol is an employee of and owns equity interest in Romark, L.C. Mathew Bardin, Jessica Fulgencio and Dena Mogelnicki are employees of Romark, L.C.; Christian Brechot is a senior adviser for Romark, L.C., an adviser for the Theravectys, Shanghai Vivo Biosciences and the chairman of The Healthy Aging company.Clinical TrialNCT04486313Funding StatementThis study was funded by the Romark Institute of Medical Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IntegReview IRB 3815 S. Capital of Texas Highway Suite 320 Austin, Texas 78704All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesReasonable requests from qualified researchers will be considered for data sharing. These requests should be submitted to medinfo@romark.com.